Rep. C. Scott Franklin Purchases Shares of Novo Nordisk A/S (NYSE:NVO)

Representative C. Scott Franklin (R-Florida) recently bought shares of Novo Nordisk A/S (NYSE:NVO). In a filing disclosed on April 11th, the Representative disclosed that they had bought between $15,001 and $50,000 in Novo Nordisk A/S stock on March 27th. The trade occurred in the Representative’s “FIDELITY TRADITIONAL IRA” account.

Representative C. Scott Franklin also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Novo Nordisk A/S (NYSE:NVO) on 3/27/2025.
• Purchased $50,001 – $100,000 in shares of Amazon.com (NASDAQ:AMZN) on 2/26/2025.
• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 2/26/2025.
• Purchased $15,001 – $50,000 in shares of Lockheed Martin (NYSE:LMT) on 2/18/2025.
• Purchased $1,001 – $15,000 in shares of Lockheed Martin (NYSE:LMT) on 2/18/2025.
• Sold $1,000,001 – $5,000,000 in shares of The Baldwin Insurance Group (NASDAQ:BWIN) on 2/7/2025.
• Sold $15,001 – $50,000 in shares of The Baldwin Insurance Group (NASDAQ:BWIN) on 2/6/2025.
• Sold $50,001 – $100,000 in shares of Costco Wholesale (NASDAQ:COST) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of Costco Wholesale (NASDAQ:COST) on 1/28/2025.

Novo Nordisk A/S Price Performance

NYSE NVO traded down $1.60 during trading hours on Tuesday, reaching $64.46. The company’s stock had a trading volume of 5,940,900 shares, compared to its average volume of 5,834,093. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. Novo Nordisk A/S has a 1-year low of $59.32 and a 1-year high of $148.15. The company’s 50-day moving average is $77.48 and its two-hundred day moving average is $92.95. The firm has a market capitalization of $289.27 billion, a price-to-earnings ratio of 19.59, a P/E/G ratio of 0.90 and a beta of 0.61.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which was paid on Tuesday, April 8th. Investors of record on Monday, March 31st were paid a $0.7874 dividend. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend was Monday, March 31st. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s payout ratio is currently 49.54%.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an “equal weight” rating for the company. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Finally, BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $145.25.

Hedge Funds Weigh In On Novo Nordisk A/S

Institutional investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP acquired a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at about $42,017,000. Sunbelt Securities Inc. lifted its stake in shares of Novo Nordisk A/S by 17.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 12,586 shares of the company’s stock valued at $1,499,000 after purchasing an additional 1,834 shares during the last quarter. Soltis Investment Advisors LLC purchased a new position in shares of Novo Nordisk A/S during the 3rd quarter worth $258,000. Passumpsic Savings Bank increased its position in shares of Novo Nordisk A/S by 0.9% during the 3rd quarter. Passumpsic Savings Bank now owns 21,448 shares of the company’s stock worth $2,554,000 after purchasing an additional 194 shares during the last quarter. Finally, Virtu Financial LLC raised its holdings in Novo Nordisk A/S by 69.8% in the 3rd quarter. Virtu Financial LLC now owns 33,929 shares of the company’s stock valued at $4,040,000 after buying an additional 13,949 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

About Representative Franklin

Scott Franklin (Republican Party) is a member of the U.S. House, representing Florida’s 18th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Franklin (Republican Party) is running for re-election to the U.S. House to represent Florida’s 18th Congressional District. He declared candidacy for the 2026 election.

Scott Franklin was born in Thomaston, Georgia. Franklin graduated from Lakeland High School. He served in the U.S. Navy from 1986 to 2000 and the U.S. Navy Reserve from 2000 to 2012.

Franklin earned a B.S. from the United States Naval Academy in 1986 and an M.B.A. from Embry-Riddle Aeronautical University in 1994. Franklin’s career experience includes owning an insurance agency and working as a naval aviator with the U.S. Navy.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.